Hsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNX

Hsbc Holdings PLC decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 34.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,815 shares of the biotechnology company’s stock after selling 29,002 shares during the period. Hsbc Holdings PLC owned about 0.11% of REGENXBIO worth $390,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,982 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of REGENXBIO by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 2,326 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of REGENXBIO by 22.4% during the 4th quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 2,800 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of REGENXBIO by 2.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,452 shares of the biotechnology company’s stock worth $775,000 after acquiring an additional 2,827 shares in the last quarter. Finally, Voya Investment Management LLC boosted its position in shares of REGENXBIO by 7.5% during the 4th quarter. Voya Investment Management LLC now owns 43,502 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 3,024 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RGNX. Royal Bank Of Canada reduced their price target on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 9th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of REGENXBIO in a research report on Tuesday, August 19th. Barclays cut their target price on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus price target of $28.38.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $9.12 on Wednesday. The firm has a market cap of $460.65 million, a PE ratio of -2.65 and a beta of 1.17. The firm’s fifty day moving average is $8.59 and its 200-day moving average is $8.13. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $13.48.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. Sell-side analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.